Skip to main content

Measuring the Utility of Prenatal Exome Sequencing Using the Clinician-Reported Genetic Testing Utility InDEx for Prenatal Care: A Retrospective Multicentre Study

In brief

Prenatal exome sequencing found a diagnosis in 42% of selected pregnancies

In this retrospective study of 115 pregnancies referred for testing at five Ontario clinics, prenatal exome sequencing produced a diagnosis in 41.7%. Clinicians rated testing as more useful when results were positive, more eligibility criteria were met, and the pregnancy was ongoing at result disclosure. The findings support its clinical value, but rely on clinician-reported assessments in a selected cohort.

Journal
Prenatal diagnosis (Q1)
Published
11 November 2026
Study design
Retrospective cohort
Evidence level
Level 3, Low (CEBM 3b)
Authors
Robin Z Hayeems, Stephanie Luca, Bowen Xiao, David Chitayat, Erin Mathews, Sankavi Mohanathas, et al.
PMID
43013894
DOI
10.1002/pd.70306

Why clinicians should know about it

  • Picked for Genetics (clinical) (top studies of the week, 15 November 2026): Prenatal exome yield and clinical utility inform genetic testing

Abstract

OBJECTIVE: To assess the diagnostic and clinical utility of prenatal exome sequencing (ES) in a cohort of pregnancies using the Clinician-reported Genetic testing Utility InDEx for Prenatal Care (C-GUIDE Prenatal). METHODS: Cases that met criteria for prenatal ES in Ontario, Canada were identified in 5 clinics. Clinicians assessed the utility of ES using C-GUIDE Prenatal, a clinician-reported measure of how genetic testing informs pregnancy and neonatal management. Case characteristics were summarized descriptively. C-GUIDE Prenatal total scores were calculated and regressed against clinically important variables using generalised estimating equations. RESULTS: Among 115 cases, the diagnostic yield was 41.7%. The mean C-GUIDE Prenatal score was 9.48 (SD 11.51). Compared with negative results, informative positive results were associated with an increase in C-GUIDE Prenatal score of 17.6 (p < 0.001). Compared to meeting one criterion for ES, meeting ≥ 3 criteria was associated with an increase in C-GUIDE Prenatal score of 3.8 (p < 0.05). Compared with pregnancies that were not ongoing at result disclosure, ongoing pregnancy was associated with an increase in the C-GUIDE Prenatal score of 2.8 (p < 0.001). CONCLUSION: Findings address a knowledge gap in the clinical value evidence base that informs policy and funding decision-making for prenatal genetic testing.

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.